Latest News-四川科伦博泰生物医药股份有限公司 Mediaroom_Page

Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC

CHENGDU, China, March 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("...

2026-03-24 17:24 5203

KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF

* Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximatel...

2026-03-24 10:44 5882

Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study

CHENGDU, China, March 18, 2026 /PRNewswire/ -- The 2026 European Lung Cancer Congress (ELCC) will b...

2026-03-18 22:31 9291

Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study

Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis

CHENGDU, China, March 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("K...

2026-03-09 19:39 6249

Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer

CHENGDU, China, Feb. 6, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Ke...

2026-02-06 17:00 8825

Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference

CHENGDU, China, Jan. 16, 2026 /PRNewswire/ -- From January 12 to 15, 2026, the 44th J.P. Morgan Hea...

2026-01-16 02:30 13024

Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies

CHENGDU, China, Jan. 6, 2026 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference (JPMHC) wil...

2026-01-07 10:44 12406

Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Ke...

2026-01-05 20:00 9465

Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Ke...

2026-01-05 17:29 14703

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-dire...

2025-12-04 19:50 4652

The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma

CHENGDU, China, Nov. 28, 2025 /PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-B...

2025-11-28 12:32 3909

Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint

CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (th...

2025-11-24 20:00 2846

Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress

CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Ho...

2025-11-10 10:01 2790

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

* After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and...

2025-10-20 17:06 2174

Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (th...

2025-10-20 13:59 2239

Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO

Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (th...

2025-10-20 10:36 2997

Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (th...

2025-10-18 22:46 3483

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC

CHENGDU, China, Oct. 17, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (th...

2025-10-17 20:22 2790

Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress

CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- The 2025 European Society for Medical Oncology (ESMO...

2025-09-23 17:03 2604

Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC

CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (t...

2025-09-23 10:22 2116